Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723689 | 0.85 | LMNA (0.63) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL11670709 | 0.84 | TSHR (0.71) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL7867200 | 0.83 | CYP3A4 (0.61) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL11709815 | 0.83 | TRPM8 (0.57) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL8751588 | 0.82 | TSHR (0.52) | CYP3A4LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL11589439 | 0.82 | ALDH1A1 (0.47) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL11652965 | 0.82 | TRPM8 (0.56) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL30957369 | 0.81 | TP53 (0.61) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL30957368 | 0.81 | TP53 (0.61) | CYP3A4LMNATRPM8TSHRNPSR1 | |
| SCHEMBL1114970 | 0.81 | CYP3A4 (0.55) | CYP3A4LMNATRPM8TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4162362-A | CONDESATION OF N-ARYL CARBAMIC ACID ESTER WITH FORMALDEHYDE IN THE PRESENCE OF A SULFONIC ACID | ATLANTIC RICHFIELD COMPANY (US) | 1979-07-24 | — | — | US | claimed |
| WO-2023130050-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| WO-2002072025-A2 | IMPROVING POSTSYNAPTIC RESPONSE BY A COMBINATION OF 4-MINOPYRIDINE AND AGONIST | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-0016441-B1 | A METHOD FOR THE PREPARATION OF A MIXTURE OF DIPHENYL METHANE DICARBAMATES AND POLYMETHYLENE POLYPHENYL CARBAMATES | ATLANTIC RICHFIELD COMPANY (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4230877-A | ACID CATALYZED CONDENSATION OF AN N-ARYL CARBAMIC ACID ESTER WITH A CARBONYL COMPOUND | ATLANTIC RICHFIELD COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP3A4 2139/4885LMNA 4656/4885TRPM8 438/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP3A4 2507/4885LMNA 4671/4885TRPM8 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.